Steroid Avoidance or Withdrawal After Renal Transplantation Increases the Risk of Acute Rejection but Decreases Cardiovascular Risk. A Meta-Analysis
The DOI matches its Crossref record; 112 of the 113 references it cites were found in a registry or an index.
Abstract
Introduction The morbidity related to long-term steroid therapy has led to continued interest in withdrawal of steroids from immunosuppressant regimens after renal transplantation. A number of recent trials have provided long-term information regarding the risks and benefits of steroid avoidance or withdrawal (SAW). Methods A literature search was performed using Ovid Medline, Embase, the Cochrane Library, and the Transplant Library. Randomized controlled trials comparing a maintenance steroid group with complete avoidance or withdrawal of steroids were selected. All studies were assessed for methodological quality. Trials were pooled by meta-analysis to provide summary effects (relative risk [RR] or weighted mean difference) with 95% confidence intervals (CI). Results Thirty-four studies including 5,637 patients met the inclusion criteria. SAW regimens significantly increased the risk of acute rejection (AR) over maintenance steroids (RR 1.56, CI 1.31-1.87, P Conclusion Despite an increase in the risk of AR with SAW protocols, there is only a small effect on graft function with no measurable effect on graft or patient survival. There are significant benefits in cardiovascular risk profiles after SAW. SAW protocols would seem justified with current immunosuppressive protocols in low-risk recipients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Other more unique risk factors in this population include genetic polymorphisms, polycystic kidney disease, hepatitis C, and cytomegalovirus status.1579–1581”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1579]
In the citing paper
“An increasing body of new literature points to the association of immune checkpoint inhibitors with new-onset hyperglycemia and DM.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1579]
In the citing paper
“At this time, most of the literature is in the form of case reports demonstrating hyperglycemia, new-onset diabetes, and DKA, either with or without autoimmune markers of T1D.1579,1600–1605”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1579]
Citations
Cites
Quantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763 · cited 1×
“Heterogeneity was quantified using the I(2) test, which describes the percentage of total variation across the studies that is due to heterogeneity rather than chance (17).”
MethodAssessing the quality of reports of randomized clinical trials: Is blinding necessary?
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00134-4 · Cited by 17,582 · cited 1×
“Quality was assessed both by means of the Jadad score (a score of 3 or greater is considered good quality) and a description of allocation concealment and analysis based on intention-totreat (15).”
MethodParmar, M. K. B., Torri, V., & Stewart, L. (1998) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19981230)17:24<2815::aid-sim110>3.0.co;2-8 · Cited by 4,802 · cited 2×
“2 (46) 57±20 (25) 66±33 (42) 47±17 (49) Maintenance Mean ± sd (N) 58.”
MethodInteraction revisited: the difference between two estimates.
Altman, D. G., & Bland, J. M. (2003) · BMJ · doi:10.1136/bmj.326.7382.219 · Cited by 3,203 · cited 2×
“Subgroups were compared using the interaction method described by Altman and Bland (28), with a significance level of P less than 0.”
InfluentialRosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis
Fellström, B. C., Jardine, A. G., Schmieder, R. E., Holdaas, H., Bannister, K., Beutler, J., Chae, D.-W., Chevaile, A., Cobbe, S. M., Grönhagen-Riska, C., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810177 · Cited by 2,036 · cited 3×
“2 (42) 161±65 (44) Maintenance Mean ± sd (N) 184.”
ResultImputing missing standard deviations in meta-analyses can provide accurate results
Furukawa, T. A., Barbui, C., Cipriani, A., Brambilla, P., & Watanabe, N. (2006) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2005.06.006 · Cited by 1,568 · cited 1×
“Otherwise, a pooled standard deviation was calculated for all similar studies in the current meta-analysis and applied to studies with missing values (27).”
MethodLong-term survival in renal transplant recipients with graft function
Ojo, A. O., Hanson, J. A., Wolfe, R. A., Leichtman, A. B., Agodoa, L. Y., & Port, F. K. (2000) · Kidney International · doi:10.1046/j.1523-1755.2000.00816.x · Cited by 810 · cited 2×
“Death with a functioning graft is an important cause of graft loss after renal transplantation, accounting for more than 40% of graft losses in one registry analysis (2).”
BackgroundWoodle, E. S., First, M. R., Pirsch, J., Shihab, F., Gaber, A. O., & Van Veldhuisen, P. (2008) · Annals of Surgery · doi:10.1097/sla.0b013e318187d1da · Cited by 474
A Meta-Analysis of Immunosuppression Withdrawal Trials in Renal Transplantation
KASISKE, B. L., CHAKKERA, H. A., LOUIS, T. A., & MA, J. Z. (2000) · Journal of the American Society of Nephrology · doi:10.1681/asn.v11101910 · Cited by 392
Experience in Renal Transplantation
Starzl, T. E. (1965) · The American Journal of the Medical Sciences · doi:10.1097/00000441-196505000-00064 · Cited by 363
Research works printed but not linked: 41
- Tan, 2006, Safety and efficacy of steroid withdrawal in modern triple immunosuppressant: A systematic review [Chinese]., Chin J Evid Based Med, 6, 273
- Vincenti, 2005, 3 months interim results of a 12-month study with enteric-coated mycophenolate sodium (EC-MPS, Myfortic®), basiliximab, and neoral C-2 comparing different steroid protocols in de novo kidney recipients [abstract]., J Am Soc Nephrol, 16, 236a
- Walker, 2005, Preliminary results of a 12-month study with enteric-coated mycophenolate sodium (EC-MPS), basiliximab, and neoral C-2 comparing two investigational steroid regimens (without steroids or short-term use of steroids) with standard steroid treatment in de novo kidney recipients [abstract]., Nephrology, 10, A214
- Vincenti, 2006, Metabolic effects of steroid avoidance or early steroid withdrawal: 12-month results of a randomised trial in de novo renal transplant patients receiving cyclosporine, enteric-coated mycophenolate sodium (EC-MPS) and basiliximab [abstract]., Am J Transplant, 6, 483
- Schena, 2006, 12-month results of a prospective, randomised trial of steroid avoidance, steroid withdrawal and standard steroids in de novo renal transplant patients receiving cyclosporine, enteric-coated mycophenolate sodium (EC-MPS) and basiliximab [abstract]., Am J Transplant, 6, 84
- Vincenti, 2005, Preliminary 3-month results comparing immunosuppressive regimens of enteric-coated mycophenolate sodium (EC- MPS) without steroids vs short-term use of steroids vs standard steroid treatment including basiliximab, and neoral C-2 in de novo kidney recipients abstract., Am J Transplant, 5, 548
- Walker, 2007, Comparison of metabolic parameters in renal transplant patients randomised to steroid avoidance, steroid withdrawal or standard steroids within a 12 month randomised multicentre trial [abstract]., Transplant Soc Aust N Z, 32
- Ing, 2007, Bone mineral density changes in a prospective randomized trial of steroid withdrawal in kidney transplant recipients abstract., Am J Transplant, 7, 310
- Stiller, 1983, The requirements for maintenance steroids in cyclosporine-treated renal transplant recipients., Transplant Proc, 15, 2490
- De Vecchi, 1985, Need for steroid in cyclosporine (Cy) treated cadaveric renal transplant recipients (pts) [abstract]., Kidney Int, 28, 394
- Griffin, 1986, Renal transplantation without steroids: A controlled clinical trial., Transplant Proc, 18, 797
- Nott, 1985, Low-dose steroids do not augment cyclosporine immunosuppression but do diminish cyclosporine nephrotoxicity., Transplant Proc, 17, 1289
- Johnson, 1990, Prospective trials with cyclosporine monotherapy in cadaver renal transplantation., J Nephrol, 3, 47
- Tarantino, 2000, Long-term results of a randomized trial of 3 cyclosporine (CSA) regimens in cadaveric kidney allografts (TXC) [abstract]., Nephrol Dial Transplant, 15, 250
- Klinger, 2003, Large, prospective study evaluating steroid-free immunosuppression with tacrolimus/basiliximab and tacrolimus/MMF compared with tacrolimus/MMF/steroids in renal transplantation [abstract]., Nephrol Dial Transplant, 18, 788
- Kramer, 2003, Two steroid-free immunosuppressive regimens (basiliximab/tacrolimus and tacrolimus/MMF) in comparison to tacrolimus/MMF/steroid therapy after renal transplantation [abstract]., J Am Soc Nephrol, 14, 9a
- Kramer, 2004, 1-year follow-up of two steroid-free immunosuppressive regimens—Basiliximab/Tacrolimus and tacrolimus/MMF—In comparison to tacrolimus/MMF/steroids after renal transplantation [abstract]., J Am Soc Nephrol, 15, 289a
- Vitko, 2003, Comparison of two steroid-free regimens—Basiliximab/Tacrolimus and Tacrolimus/MMF—With Tacrolimus/MMF/Steroid Therapy After Renal Transplantation [abstract]., Am J Transplant, 3, 312
- Pankewycz, 2004, The clinical benefits of early steroid withdrawal (7 days) and utility of protocol biopsies at 1, 6 and 12 months in guiding steroid-free immunosuppressive therapy after renal transplantation [abstract]., Am J Transplant, 4, 579
- Pankewyez, 2003, Induction immunosuppression for renal transplantation using thymoglobulin, FK506 and mycophenolate mofetil allows for safe steroid withdrawal and eliminates the need for early protocol biopsies [abstract]., Am J Transplant, 3, 478
- Gaber, 2006, Characteristics of rejection in renal allografts following early corticosteroid withdrawal in a randomized controlled clinical trial: Results of a 3 year follow-up [abstract]., Transplantation, 82, 178
- Pirsch, 2006, Effect of steroid withdrawal on new onset diabetes after transplant: Results of a randomized double blinded placebo controlled trial [abstract]., Transplantation, 82, 355
- Woodle, 2007, A randomized double blind, placebo-controlled trial of early corticosteroid cessation versus chronic corticosteroids: Four year results [abstract]., Am J Transplant, 7
- Woodle, 2006, Comparison of T cell depleting and non-t cell depleting antibody induction therapy for early corticosteroid withdrawal regimens abstract., Transplantation, 82, 353
- Woodle, 2008, A randomsied double blind, placebo-controlled trial of early corticosteroid cessation versus chronic corticosteroids: Five year results., Am J Transplant, 8, 300
- Nematalla, 2007, Improving quality of life after steroid avoidance immunosuppression regimen in live donor renal allotransplant recipients—A prospective randomized controlled study single center experience (Two year follow up) [abstract]., Transpl Int, 20, 134
- Aswad, 1998, Steroid withdrawal in living related kidney transplant patients receiving FK506 [abstract]., Nephrol Dial Transplant, 13, A285
- Burke, 2001, Double-blind, placebo-controlled trial of steroid withdrawal in kidney transplant recipients with a cyclosporine/mycophenolate regimen-three year follow up [abstract]., Am J Transplant, 1, 296
- Francos, 2002, Double-blind, placebo-controlled, 3 year study of steroid withdrawal using a neoral and mycophenylate mofetil (MMF)-based immunosuppressive regimen in primary renal transplant recipients [abstract]., Am J Transplant, 2, 172
- Boletis, 2002, Steroids withdrawal in renal transplant recipients: A randomized controlled study [abstract]., Nephrol Dial Transplant, 17, 312
- Smak Gregoor, 2001, A prospective randomised study of withdrawal of cyclosporine or prednisone in renal transplant recipients treated with mycophenolate mofetil, cyclosporine, and prednisone: 18 months follow-up data [abstract]., Am J Transplant, 1, 246
- Smak Gregoor, 2003, Long-term results of a randomized, prospective study after withdrawal of cyclosporine or prednisone in renal transplant recipients treated with mycophenolate mofetil, cyclosporine, and prednisone [abstract]., Am J Transplant, 3, 217
- Jindal, 2002, Reduction of high cholesterol levels by early withdrawal of steroids from a tacrolimus-based triple regimen [abstract]., Am J Transplant, 2, 190
- Pascual, 2004, Long-term efficacy and safety of steroid withdrawal in tacrolimus-treated renal transplant recipients: Results of a 3 year followup., Am J Transplant, 4, 578
- van Hooff, 2001, First, large, prospective study of a controlled withdrawal of steroids or MMF following three months of tacrolimus/MMF/steroid therapy abstract., J Am Soc Nephrol, 12, 920a
- Dudley, 1994, Effect of steroid withdrawal on graft function in renal transplant recipients [abstract]., Nephrol Dial Transplant, 9, 1672
- Hollander, 1996, Late prednisone withdrawal in renal transplant patients [abstract]., J Am Soc Nephrol, 7, 1911
- Matl, 2000, Withdrawal of steroids from the triple-drug therapy in renal transplant patients., Casopis Lekaru Ceskych, 139, 115
- Matl, 1998, Withdrawal of steroids from triple drug therapy in renal transplant patients [abstract]., Nephrol Dial Transplant, 13, A256
- Farmer, 2001, What is the value of short synacthen tests in predicting the ease of steroid withdrawal in renal transplant recipients? A randomised controlled trial [abstract]., Am J Transplant, 1, 190
- Akin, 2004, Five year follow-up after steroid withdrawal demonstrates no evidence of worsening renal function [abstract]., Am J Transplant, 4, 298
Cited by
Items 101–200 of 264
Prevention and management of transplant-associated diabetes
Jenssen, T. G., & Hartmann, A. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.628936 · Cited by 17
“Another review including both early- and latephase withdrawal of prednisolone found that the incidence of NODAT was reduced by 36% but at the cost of a higher incidence of acute rejections [44].”
BackgroundCulliford, A., Phagura, N., & Sharif, A. (2020) · Transplantation Direct · doi:10.1097/txd.0000000000000989 · Cited by 17
van den Born, J. C., Meziyerh, S., Vart, P., Bakker, S. J. L., Berger, S. P., Florquin, S., de Fijter, J. W., Neto, A. W. G., Idu, M. M., Pol, R. A., et al. (2023) · Transplantation · doi:10.1097/tp.0000000000004776 · Cited by 17
“These findings are in line with previous studies, 9,39 and especially in the light of the known cardiovascular burden of transplantation patients in the long term, 40,41 an important outcome.”
ResultStevens, R. B., Foster, K. W., Miles, C. D., Lane, J. T., Kalil, A. C., Florescu, D. F., Sandoz, J. P., Rigley, T. H., Nielsen, K. J., Skorupa, J. Y., et al. (2014) · Transplantation · doi:10.1097/tp.0000000000000250 · Cited by 15
“1-3 [12-16] 15.”
Barbour, S. J., Djurdjev, O., Gill, J. S., Dong, J. J., & Gill, J. (2019) · Kidney International · doi:10.1016/j.kint.2019.02.041 · Cited by 16
Lim, C. C., Choo, J. C. J., Tan, H. Z., Mok, I. Y. J., Chin, Y. M., Chan, C. M., & Woo, K. T. (2021) · Kidney Research and Clinical Practice · doi:10.23876/j.krcp.20.174 · Cited by 19
Sridhar, V. S., Ambinathan, J. P. N., Gillard, P., Mathieu, C., Cherney, D. Z. I., Lytvyn, Y., & Singh, S. K. (2021) · Transplantation · doi:10.1097/tp.0000000000003919 · Cited by 15
Aull, M. J., Dadhania, D. M., Afaneh, C. I., Leeser, D. B., Hartono, C., Lee, J. B., Serur, D. S., Pizzo, J. J. D., Suthanthiran, M., & Kapur, S. (2012) · Transplantation · doi:10.1097/tp.0b013e318265c461 · Cited by 16
“Long-term use of corticosteroids (CSs) after transplantation increases morbidity and health-related costs (1).”
BackgroundTao, Z., Luo, Z., Zou, Z., Ye, W., Hao, Y., Li, X., Zheng, K., Wu, J., Xia, J., Zhao, Y., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1580369 · Cited by 14
“Notably, while discontinuation mitigates metabolic disturbances, it concomitantly elevates rejection risk due to rebound immune activation (204).”
Posttransplant Hypertension: Multipathogenic Disease Process
Barbari, A. (2013) · Experimental and Clinical Transplantation · doi:10.6002/ect.2012.0311 · Cited by 14
Steroid avoidance/withdrawal and maintenance immunosuppression in pediatric kidney transplantation
Kizilbash, S. J., Jensen, C. J., Kouri, A. M., Balani, S. S., & Chavers, B. M. (2021) · Pediatric Transplantation · doi:10.1111/petr.14189 · Cited by 16
Stumpf, J., Thomusch, O., Opgenoorth, M., Wiesener, M. S., Pascher, A., Woitas, R. P., Suwelack, B. M., Rentsch, M., Witzke, O., Rath, T., et al. (2023) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfad130 · Cited by 17
“Conversely, corticosteroid-free or -withdrawal regimens were frequently associated with increased T cell–mediated acute rejection rates [5 , 6 ], while long-term data on the frequency of HLA-sensitization and humoral rejections are rare.”
BackgroundWillicombe, M. K., Kumar, N., Goodall, D., Clarke, C., McLean, A. G., Power, A. J., & Taube, D. H. (2014) · Clinical Transplantation · doi:10.1111/ctr.12476 · Cited by 14
Treatment-Resistant Hypertension in the Transplant Recipient
Lakkis, J. I., & Weir, M. R. (2014) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2014.08.010 · Cited by 14
Gaber, A. O., Moore, L. W., Alloway, R. R., Woodle, E. S., Pirsch, J. D., Shihab, F. S., Henning, A., Fitzsimmons, W. E., Holman, J., Reisfield, R., et al. (2013) · Transplantation · doi:10.1097/tp.0b013e3182777efb · Cited by 14
“However, Knight and Morris recently published a meta-analysis of 34 studies reporting various methods of steroid withdrawal or avoidance that demonstrate a slight increase in the risk of acute rejection (4).”
BackgroundIs it safe to withdraw steroids within seven days of renal transplantation?
Zhang, X., Huang, H., Han, S., Fu, S., & Wang, L. (2012) · Clinical Transplantation · doi:10.1111/ctr.12015 · Cited by 13
Lopez‐Soler, R. I., Chan, R. W.-Y., Martinolich, J. L., Park, L., Ata, A., Chandolias, N., & Conti, D. J. (2016) · Clinical Transplantation · doi:10.1111/ctr.12878 · Cited by 16
Tsai, Y., Liu, F.-C., Kuo, C., Chung, T., & Yu, H. (2018) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s164323 · Cited by 12
“31,32 A recently updated review reported that steroid avoidance and withdrawal for KTRs increase the rate of acute rejection but showed no difference in graft and patient survival for 5-year follow-up after kidney transplantation.”
Brakemeier, S., Arns, W., Lehner, F., Witzke, O., Vonend, O., Sommerer, C., Mühlfeld, A., Rath, T., Schuhmann, R., Zukunft, B., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0222730 · Cited by 12
Vock, D. M., & Matas, A. J. (2019) · Transplant International · doi:10.1111/tri.13530 · Cited by 12
Hernández, D., Alonso-Titos, J., Vázquez, T., León, M., Caballero, A., Cobo, M. Á., Sola, E., López, V., Esteban, P. R., Cruzado, J. M., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10092005 · Cited by 11
Sierra, J. A., Campos, E. R., Cardona-Muñóz, E. G., Evangelista‐Carrillo, L. A., Gómez-Navarro, B., González-Espinoza, E., Lugo-López, O., Cerrillos‐Gutiérrez, J. I., Medina‐Pérez, M., Jalomo‐Martínez, B., et al. (2016) · Transplantation Proceedings · doi:10.1016/j.transproceed.2015.12.013 · Cited by 12
Role of steroid maintenance in sensitized kidney transplant recipients
Sureshkumar, K. K., Marcus, R. J., & Chopra, B. (2015) · World Journal of Transplantation · doi:10.5500/wjt.v5.i3.102 · Cited by 12
New-onset diabetes mellitus after renal transplantation
Goldmannová, D., Karásek, D., Krystyník, O., & Zadražil, J. (2016) · Biomedical Papers · doi:10.5507/bp.2016.005 · Cited by 16
Engberg, H., Wehberg, S., Bistrup, C., Heaf, J. G., Sørensen, S. S., Thiesson, H. C., Hansen, J. M., Svensson, M. H. S., Green, A., & Marckmann, P. (2016) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfw304 · Cited by 12
John, E. G., & Domingo, L. (2014) · PubMed Central · Cited by 11
Bae, S., Chen, Y., Sandal, S., Lentine, K. L., Schnitzler, M. A., Segev, D. L., & McAdams‐DeMarco, M. (2024) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfae218 · Cited by 13
CARDIOVASCULAR DISEASE IN RENAL TRANSPLANT RECIPIENTS
McQuarrie, E. P., Fellström, B., Holdaas, H., & Jardine, A. G. (2010) · Journal of Renal Care · doi:10.1111/j.1755-6686.2010.00160.x · Cited by 11
“Minimisation of steroid dose reduces the risk of PTDM and may reverse diabetes, and restore insulin sensitivity (Wilkinson et al. 2005; Knight & Morris 2010).”
BackgroundZhang, J., Qiu, J., Chen, G., Wang, C., Wang, C., Yu, S., & Chen, L. (2018) · Renal Failure · doi:10.1080/0886022x.2018.1455592 · Cited by 15
“A meta-analysis showed that early steroid avoidance or withdrawal after renal transplantation increased the risk of late AR [13].”
Early steroid withdrawal in HIV-infected kidney transplant recipients: Utilization and outcomes
Werbel, W. A., Bae, S., Yu, S., Ammary, F. A., Segev, D. L., & Durand, C. M. (2020) · American Journal of Transplantation · doi:10.1111/ajt.16195 · Cited by 11
NEW ONSET OF DIABETES MELLITUS IN INDIAN RENAL TRANSPLANT RECIPIENT-A RETROSPECTIVE STUDY
Patel, D. S., Modi, K., Patel, A. K., & Chaudhary, V. (2015) · International Journal of Pharmacy and Pharmaceutical Sciences · Cited by 11
Bossini, N., Sandrini, S., Casari, S., Tardanico, R., Maffeis, R., Setti, G., Valerio, F., Forleo, M. A., Nodari, F., & Cancarini, G. C. (2014) · Transplant International · doi:10.1111/tri.12377 · Cited by 12
“The high incidence of morbidity and mortality resulting from cardiovascular issues in HIV-infected patients [13,14] and the negative effects of prolonged steroid use on conditions associated with cardiovascular risk, such as diabetes, dyslipidemia, and hypertension, are unquestionable [24,25].”
BackgroundCorticosteroid minimization in renal transplantation: Careful patient selection enables feasibility
Vlachopanos, G., Bridson, J.-M., Sharma, A. K., & Halawa, A. M. (2016) · World Journal of Transplantation · doi:10.5500/wjt.v6.i4.759 · Cited by 12
Thierry, A., Mourad, G., Büchler, M., Kamar, N., Villemain, F., Heng, A. ‐., Meur, Y. L., Choukroun, G., Toupance, O., Legendre, C., et al. (2012) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfs146 · Cited by 11
“Reported elsewhere, 1-year [12] and 5-year [10] follow-up data have shown a reduced requirement for hypoglycaemic treatment following very early steroid withdrawal, while a meta-analysis involving 5537 patients found the rate of new-onset diabetes to be significantly reduced with steroid avoidance or withdrawal [28].”
Backgroundde Vries, L. V., de Jong, W. H. A., Touw, D. J., Berger, S. P., Navis, G., Kema, I. P., & Bakker, S. J. L. (2017) · Steroids · doi:10.1016/j.steroids.2017.09.001 · Cited by 11
“Nevertheless, it has recently been concluded that corticosteroids have to remain part of the immunosuppressive regimen in order to maintain low acute rejection rates and optimal long-term graft survival [10,11].”
Knight, S. R., & Morris, P. J. (2011) · Transplantation · doi:10.1097/tp.0b013e3182370611 · Cited by 11
Self-citationNew Onset Diabetes After Organ Transplantation: Risk Factors, Treatment, and Consequences
Popović, L., & Bulum, T. (2025) · Diagnostics · doi:10.3390/diagnostics15030284 · Cited by 17
“Short-term corticosteroid pulse therapy post-transplant, combined with low-dose corticosteroids for maintenance, has been found to reduce the risk of developing NODAT [56].”
Steroid Avoidance or Withdrawal After Kidney Transplantation: A Balancing Act
Sprangers, B., & Vanrenterghem, Y. F. C. (2010) · Transplantation · doi:10.1097/tp.0b013e3181e5927a · Cited by 10
“The first by Knight and Morris (2) examines four groups of recipients, namely those in whom steroids are avoided, those in whom steroids were used for 7 days or less, those in whom steroids were withdrawn between 7 days and 12 months, and finally those in whom withdrawal took place after 12 months.”
BackgroundFaulhaber, M., Maeding, I., Malehsa, D., Raggi, M. C., Haverich, A., & Bara, C. (2013) · International Immunopharmacology · doi:10.1016/j.intimp.2013.02.012 · Cited by 10
(2011) · PubMed · Cited by 10
Desai, V. C. A., Ferrand, Y., Cavanaugh, T. M., Kelton, C. M. L., Caro, J. J., Goebel, J., & Heaton, P. C. (2017) · Medical Decision Making · doi:10.1177/0272989x17700879 · Cited by 10
“001) in patients avoiding or withdrawing early from steroids.(52) Potent induction agents in the steroid avoidance regimen could also be responsible for the higher number of fractures observed relative to the other regimens in the DES.”
ResultEverolimus in kidney transplant recipients at high cardiovascular risk: a narrative review
ENTROPIA Project, Paoletti, E., Citterio, F., Corsini, A., Potena, L., Rigotti, P., Sandrini, S., Bussalino, E., & Stallone, G. (2019) · Journal of Nephrology · doi:10.1007/s40620-019-00609-y · Cited by 11
“Several studies have shown that long-term steroid therapy is associated with increased risk of new-onset diabetes after transplantation (NODAT), hypertension and dyslipidemia [5, 8], all well-known cardiovascular risk factors.”
BackgroundPathak, V., Madhavan, D., Narayanasamy, K., Kumar, S., Ramalingam, V., Sengodagounder, B., & Bodonyi-Kovacs, G. (2019) · Transplantation Direct · doi:10.1097/txd.0000000000000923 · Cited by 9
Novel management of diabetes in kidney transplantation
Ong, S., & Rhee, C. M. (2021) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000665 · Cited by 10
Hypertension in Kidney Transplant Recipients: Where Are We Today?
Arı, E., Fıcı, F., & Robles, N. R. (2021) · Current Hypertension Reports · doi:10.1007/s11906-021-01139-4 · Cited by 10
A Review of Induction with Rabbit Antithymocyte Globulin in Pediatric Heart Transplant Recipients
Schweiger, M., Zuckermann, A. O., Beiras-Fernández, A., Berchtold‐Herz, M., Boeken, U., Garbade, J., Hirt, S. W., Richter, M., Ruhpawar, A., Schmitto, J. D., et al. (2018) · Annals of Transplantation · doi:10.12659/aot.908243 · Cited by 10
Liverman, R., Chandran, M. M., & Crowther, B. R. (2020) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2483 · Cited by 9
Aref, A., Sharma, A. K., & Halawa, A. M. (2021) · World Journal of Transplantation · doi:10.5500/wjt.v11.i4.99 · Cited by 10
Prednisone‐free maintenance immunosuppression in obese kidney transplant recipients
Matas, A. J., & Vock, D. M. (2019) · Clinical Transplantation · doi:10.1111/ctr.13668 · Cited by 10
Improving long-term outcomes of kidney transplantation: The pressure is on.
Hesselink, D. A., & Hoorn, E. J. (2014) · PubMed · Cited by 9
Bae, S., McAdams-DeMarco, M. A., Massie, A. B., Garonzik‐Wang, J., Coresh, J., & Segev, D. L. (2021) · Transplantation · doi:10.1097/tp.0000000000003777 · Cited by 8
“Subsequent studies have also found the association of ESW with lower risk of steroidrelated side effects such as diabetes, dyslipidemia, and fracture.(11-16) These findings have established ESW as a viable maintenance immunosuppression strategy in low-risk KT recipients.”
BackgroundAhmad, N., Khan, T. F. T., Nadeem, N., & Fourtounas, K. (2020) · Experimental and Clinical Transplantation · doi:10.6002/ect.2020.0067 · Cited by 8
Lum, E. L., Towns, A., Basuli, D., Pham, P.-T., Sarkar, M., & Bunnapradist, S. (2022) · Transplantation Proceedings · doi:10.1016/j.transproceed.2022.12.003 · Cited by 8
Early Steroid Withdrawal in Adult Kidney Transplantation at a Single Center
Iwamoto, H., Hama, K., Konno, O., Yokoyama, T., Kihara, Y., Jojima, Y., Nakamura, Y., Takeuchi, H., & Shimazu, M. (2012) · Transplantation Proceedings · doi:10.1016/j.transproceed.2011.12.068 · Cited by 8
Vulto, A., Minović, I., de Vries, L. V., Timmermans, A. C., van Faassen, M. H. J. R., Neto, A. W. G., Touw, D. J., de Jong, M. F. C., van Beek, A. P., Dullaart, R. P. F., et al. (2020) · Clinical Transplantation · doi:10.1111/ctr.13824 · Cited by 9
“Urinary albumin excretion (mg/24 h) 41 [11-182] 5 [3-9] <.”
Steroid Avoidance or Withdrawal in Renal Transplantation
Knight, S. R., & Morris, P. J. (2011) · Transplantation · doi:10.1097/tp.0b013e318208e6d9 · Cited by 8
“The results of this meta-analysis broadly agree with our own recently reported conclusions that although there is an increased risk of acute rejection (AR) with steroid withdrawal, this does not seem to translate to an increase in graft dysfunction or graft loss (2).”
ResultSelf-citationBetjes, M. G. H., Gestel, J. A. K.-V., Roodnat, J. I., & de Weerd, A. E. (2023) · Transplant International · doi:10.3389/ti.2023.11751 · Cited by 7
Obesity-associated Inflammation and Alloimmunity
Zhou, H., Gizlenci, M., Xiao, Y., Martin, F., Nakamori, K., Zicari, E. M., Sato, Y., & Tullius, S. G. (2024) · Transplantation · doi:10.1097/tp.0000000000005183 · Cited by 9
“26-28 The immunosuppressive function of CNIs is exerted by inhibiting dephosphorylation and activation of nuclear factor of activated T cells.”
Chon, W. J., Desai, A., Wing, C., Arwindekar, D. J., Tang, I. Y. S., Josephson, M. A., & Akkina, S. K. (2016) · International Journal of Clinical Medicine · doi:10.4236/ijcm.2016.73021 · Cited by 7
“The practice of using an RSW protocol has improved corticosteroid related complications in renal transplant recipients [8] [9] [21] [30]–[33].”
MethodMuhetaer, G., Takeuchi, H., Unezaki, S., Kawachi, S., Iwamoto, H., Nakamura, Y., Shimazu, M., Sugiyama, K., & Hirano, T. (2014) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.06.019 · Cited by 7
Manejo da doença crônica do enxerto renal
Manfro, R. C. (2011) · Brazilian Journal of Nephrology · doi:10.1590/s0101-28002011000400015 · Cited by 7
Induction Therapy: A Modern Review of Kidney Transplantation Agents
Afaneh, C. I. (2013) · Journal of Transplantation Technologies & Research · doi:10.4172/2161-0991.s4-001 · Cited by 9
Yokoyama, N., Ishimura, T., Oda, T., Ogawa, S., Yamamoto, K., & Fujisawa, M. (2018) · Transplantation Proceedings · doi:10.1016/j.transproceed.2018.01.042 · Cited by 7
Bae, S., Garonzik‐Wang, J., Massie, A. B., McAdams‐DeMarco, M., Coresh, J., & Segev, D. L. (2020) · Clinical Transplantation · doi:10.1111/ctr.14176 · Cited by 7
Koi, A., Johnson, J. C., Engebretsen, T. L., Mujtaba, M. A., Lea, A. S., Stevenson, H. L., & Kueht, M. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14111106 · Cited by 6
“…sources of the literature on early steroid withdrawal in kidney transplant recipients have shown that it might be associated with an increased incidence of biopsy-proven acute rejection, but the long-term patient outcomes are not inferior, and patients benefit from fewer adverse effects [2,24,25].”
Monfá, E., Segundo, D. S., Ruiz, J. C., Sanabria, J., Albines, Z., Rodrigo, E., Romón, Í., Asensio, E., Arias, M., & López‐Hoyos, M. (2017) · Nefrología · doi:10.1016/j.nefro.2017.02.002 · Cited by 6
Steroid free immunosuppression is associated with enhanced Th1 transcripts in kidney transplantation
Hrubá, P., Týcová, I., Krepsova, E., Girmanová, E., Sekerková, A., Slatinská, J., Stříž, I., Honsová, E., & Viklický, O. (2017) · Transplant Immunology · doi:10.1016/j.trim.2017.03.001 · Cited by 7
“This observation has clinical relevance as steroid free protocols were shown to be associated with the increased risk of acute rejections in kidney transplantation (2, 6, 7).”
BackgroundPaccagnella, C., Andreola, S., Gambaro, A., Gambaro, G., & Caletti, C. (2025) · Cardiorenal Medicine · doi:10.1159/000542378 · Cited by 7
“Steroid-sparing therapies, either as steroid-free or as early steroid withdrawal therapy, may lead to a decrease in the incidence of PTDM and an improvement in the glycemic pro fi le [58].”
Betjes, M. G. H., & de Weerd, A. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1215167 · Cited by 12
Immunosuppressive Minimization Strategies in Kidney Transplantation
Sierra, J. A., Vazquez-Galvan, P. A., Hernández-Reyes, H., Mercado-Jauregui, L. A., Chavez-Iñiguez, J. S., González-Espinoza, E., Gómez-Navarro, B., & Cerrillos‐Gutiérrez, J. I. (2018) · InTech eBooks · doi:10.5772/intechopen.77292 · Cited by 7
“[19], evaluated a meta-analysis of 34 clinical trials with 5637 patients in regimens that included withdrawal or nonuse of steroids at any time of the transplantation, and found that the withdrawal of steroids was associated with a higher incidence of AR (RR 1.”
MethodResultCzarnecka, P., Czarnecka, K., Bączkowska, T., Łągiewska, B., & Durlik, M. (2023) · PLoS ONE · doi:10.1371/journal.pone.0278894 · Cited by 5
Future Trends in Organ Transplant Recipients – Important Issues for Dermatologists
Zecher, D., & Steiger, J. U. (2012) · Current problems in dermatology · doi:10.1159/000335153 · Cited by 5
Steroid-free chronic immunosuppression in renal transplantation
Steiner, R. W. (2012) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0b013e328359226c · Cited by 5
“Knight SR, Morris PJ. Steroid avoidance or withdrawal after renal transplantation increases the risk of acute rejection but decreases cardiovascular risk: a meta-analysis.”
BackgroundResultInfluentialBagheri, L., Hami, M., Mojahedi, M. J., Sabbagh, M. G., & Ayatollahi, H. (2016) · Journal of Renal Injury Prevention · doi:10.15171/jrip.2016.17 · Cited by 5
Successful steroid withdrawal guided by surveillance biopsies—A single‐center experience
Wehmeier, C., Hirt‐Minkowski, P., Amico, P., Georgalis, A., Hopfer, H., Steiger, J. U., Dickenmann, M., & Schaub, S. (2017) · Clinical Transplantation · doi:10.1111/ctr.13181 · Cited by 5
Oh, C., Kim, S. J., Kim, J. H., & Lee, J. H. (2012) · Journal of Korean Medical Science · doi:10.3346/jkms.2012.27.4.337 · Cited by 5
“337 duction in cardiovascular risk factors (4).”
Topical Glucocorticoid Use and the Risk of Posttransplant Diabetes
Bøtker, S., Birn, H., & Øzbay, L. A. (2023) · Case Reports in Endocrinology · doi:10.1155/2023/3648178 · Cited by 4
“Although a recent retrospective analysis with a longtermfollow-up of 15 years found that rapid glucocorticoid discontinuation was associated with reduced onset of PTDM [13], a Cochrane systematic review from 2017 and a meta-analysis from 2010 found no beneft of glucocorticoid withdrawal on PTDM and also asserted an in…”
BackgroundAfaneh, C. I., Halpern, J. A., Cheng, E., Aull, M. J., Figueiro, J., Kapur, S., & Leeser, D. B. (2010) · Transplantation Proceedings · doi:10.1016/j.transproceed.2010.09.156 · Cited by 4
Donor-specific antibodies development in renal living-donor receptors: Effect of a single cohort
Sierra, J. A., Cueto-Manzano, A. M., Campos, E. R., Cardona-Muñóz, E. G., Cerrillos‐Gutiérrez, J. I., González-Espinoza, E., Evangelista‐Carrillo, L. A., Medina‐Pérez, M., Jalomo‐Martínez, B., Nieves-Hernández, J. J., et al. (2021) · International Journal of Immunopathology and Pharmacology · doi:10.1177/20587384211000545 · Cited by 4
Arterial hypertension in kidney transplantation: huge importance, but few answers
Rebelo, R. N. D. S., & Rodrigues, C. I. S. (2022) · Brazilian Journal of Nephrology · doi:10.1590/2175-8239-jbn-2022-0109en · Cited by 6
Pernin, V., Głyda, M., Viklický, O., Lõhmus, A., Wennberg, L. M., Witzke, O., von Zur‐Mühlen, B., Anaokar, S., Hurst, M., Kazeem, G., et al. (2023) · Transplantation Direct · doi:10.1097/txd.0000000000001432 · Cited by 4
“35,36 However, this increase tends to be observed in patients treated with cyclosporine rather than with tacrolimus 37,38 and does not seem to impact graft survival.”
BackgroundLadányi, Z., Bárczi, A., Fábián, A., Ujvári, A., Cseprekál, O., Kis, É., Reusz, G., Kovács, A. D., Merkely, B. P., & Lakatos, B. K. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1094765 · Cited by 4
Cantarovich, D., Hodemon-Corne, B., Trébern-Launay, K., Giral, M., Foucher, Y., & Dantan, É. (2013) · Transplantation Proceedings · doi:10.1016/j.transproceed.2012.10.055 · Cited by 4
Sureshkumar, K. K., Hussain, S. M., Thai, N. L., Ko, T. Y., Nashar, K., & Marcus, R. J. (2014) · World Journal of Transplantation · doi:10.5500/wjt.v4.i3.188 · Cited by 4
Mechanisms of Immunosuppressive Drugs
Weltz, A. S., Scalea, J. R., Popescu, M., Xu, J., & Bromberg, J. S. (2014) · Springer eBooks · doi:10.1007/978-1-4939-0342-9_12 · Cited by 4
Hardinger, K. L., Agha, I. A., & Brennan, D. C. (2016) · Springer eBooks · doi:10.1007/978-3-319-28797-3_3 · Cited by 4
Jolly, E. C., & Watson, C. J. E. (2011) · Surgery (Oxford) · doi:10.1016/j.mpsur.2011.05.001 · Cited by 4
Tsiakas, S., Angelousi, A. G., Benetou, V., Orfanos, P., Xagas, E., Boletis, J., & Marinaki, S. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13226712 · Cited by 5
“Experience from steroid avoidance or withdrawal protocols in kidney transplantation suggests a potential cardiovascular benefit in recipients not receiving glucocorticoids, but with a greater risk for acute rejection episodes [5].”
InfluentialSureshkumar, K. K., Tangirala, B., Marcus, R. J., & Hussain, S. (2013) · Indian Journal of Nephrology · doi:10.4103/0971-4065.120328 · Cited by 3
“This analysis did not have any information on the incidence or outcomes in DGF. [14] A large single center retrospective analysis involving 1241 primary kidney transplant recipients by Rizzari et al ., showed similar patient, graft, death‑censored graft, and AR free survival rates at 10 years for…”
BackgroundMethodBang, J. B., Oh, C., Kim, Y. S., Kim, S. H., Yu, H. C., Kim, C., Ju, M. K., So, B. J., Lee, S. H., Han, S. Y., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1197475 · Cited by 3
Organ Transplantation 3 Diagnosis and prevention of chronic kidney allograft loss
Kuyper, R. J., Nankivell, B. J., & Kuypers, D. R. J. (2011) · Cited by 3
Herr, F., Brunel, M., Roders, N., & Dürrbach, A. (2016) · Drugs · doi:10.1007/s40265-016-0656-2 · Cited by 4
Vinson, A. J., Thanamayooran, A., KIBERD, B. A., West, K. A., Siddiqi, F. S., Gunaratnam, L., & Tennankore, K. (2022) · Kidney360 · doi:10.34067/kid.0003742022 · Cited by 3
Core Concepts in Hypertension in Kidney Disease
Agarwal, R., & Singh, A. K. (2016) · Springer eBooks · doi:10.1007/978-1-4939-6436-9 · Cited by 4
Steroid Withdrawal in Kidney Transplantation: The Subgroup Fallacy
Steiner, R. W. (2011) · Transplantation · doi:10.1097/tp.0b013e318208e706 · Cited by 3
Unique Considerations When Managing Hypertension in the Transplant Patient
Mitema, D. G., & Schinstock, C. A. (2016) · Advances in experimental medicine and biology · doi:10.1007/5584_2016_87 · Cited by 2
“In a metaanalysis of 34 studies including 5637 kidney transplant recipients, there was a reduced incidence of hypertension in the steroid avoidance or withdrawal group, compared with those on steroids (RR 0.90, CI 0.85–0.94, P < 0.0001) (Knight and Morris 2010).”
BackgroundInfluentialDiabetes mellitus and transplantation
Paul, R., & O’Grady, J. (2011) · doi:10.1093/med/9780199235292.003.1599 · Cited by 2
Hipertensão arterial no transplante renal: grande importância, mas poucas respostas
Rebelo, R. N. D. S., & Rodrigues, C. I. S. (2022) · Brazilian Journal of Nephrology · doi:10.1590/2175-8239-jbn-2022-0109pt · Cited by 2
“Assim como os INC, os glicocorticoides são medicamentos importantes, evitando a rejeição do enxerto, porém são fatores de risco independentes para o desenvolvimento de HA com efeito dose dependente, devido à ativação de receptores mineralocorticoides, levando à retenção de água 14 .”
BackgroundZeng, Z., & Zhang, Y. (2024) · Transplantation Proceedings · doi:10.1016/j.transproceed.2024.10.012 · Cited by 2
Risks and Benefits of Glucocorticoids in ANCA-Associated Vasculitis
Rodrigues, J. C., & Walsh, M. W. (2017) · Current Treatment Options in Rheumatology · doi:10.1007/s40674-017-0081-z · Cited by 2
Metadata
- Authors
- Knight, S. R., & Morris, P. J.
- Affiliations
- University of London (GB)
- Corresponding author
- Morris, Peter J.
- ORCID
- Knight, Simon R.
- Venue
- Transplantation
- Published
- 2010-01-15
- Volume
- 89
- Issue
- 1
- Pages
- 1-14
- ISSN
- 0041-1337 (ISSN-L)
- OpenAlex
- W2006211317
- Cited by
- 265
- References
- 113
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 8 · 2023: 14 · 2022: 11 · 2021: 14 · 2020: 10 · 2019: 15 · 2018: 13 · 2017: 17 · 2016: 25 · 2015: 20 · 2014: 26 · 2013: 16 · 2012: 21
- FWCI
- 4.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Transplantation (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Transplantation › Renal Transplantation Outcomes and Treatments
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Health Sciences › Medicine › Nephrology › Renal and Vascular Pathologies
- Keywords
- steroid avoidance, corticosteroid withdrawal, kidney transplantation, acute rejection, corticosteroid-sparing immunosuppression, cardiovascular risk, hypertension, new-onset diabetes, hypercholesterolemia, graft survival, patient survival, serum creatinine
- MeSH terms
- Adrenal Cortex Hormones, Cardiovascular Diseases, Graft Rejection, Humans, Immunosuppressive Agents, Meta-Analysis as Topic, Kidney Transplantation, Survivors, Patient Selection
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.